ArticleEpilepsia open2025
Confirmatory study on the retention rate of ketogenic diet therapy and related factors in children with drug-resistant epilepsy: A single-center cohort study.
Article in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association of first-month beta-hydroxybutyrate levels with subsequent ketogenic diet response in children with drug-resistant epilepsy: a prospective cohort study.Frontiers in nutrition · 2026Article
- Motives and predictors of modified Atkins diet discontinuation as treatment of adults with drug-resistant epilepsy.Epilepsia · 2026Observational
- Confirmatory study on the retention rate of ketogenic diet therapy and related factors in children with drug-resistant epilepsy: A single-center cohort study.Epilepsia open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveTo confirm the retention rate of ketogenic diet therapy (KDT) in children with drug-resistant epilepsy and identify its related factors through a cohort analysis.
methodsThis was a single-center cohort study. Baseline data were collected, and regular follow-up was conducted after KDT treatment. The retention rate of KDT at different time points was determined. Cox regression analyses and other statistical methods were used to identify the factors related to the retention rate.
resultsA total of 337 patients were included. 43.3% (146/337) of the patients had only spasms, 16.9% (57/337) had a genetic etiology, and 14.0% (47/337) had a structural etiology. Overall, 51.9% (175/337) of the patients were classified as having infantile epileptic spasm syndrome. The median age at KDT initiation was 33 months. 38.3% (129/337) of the patients responded to KDT. The retention rate of KDT at 3, 6, 12 and 24 months were 86.6% (292/337), 62.6% (211/337), 35.0% (118/337), and 20.2% (68/337), respectively. 9.9% (56/282) stopped the treatment due to unsatisfactory seizure control and 54.6% (154/282) stopped due to a non-response. The retention rate in patients who responded to KDT was relatively greater than that in patients who did not respond to KDT [HR: 4.714 (95% CI: 3.493, 6.362), p < 0.001]. The retention rate of KDT at 3 months was associated with seizure type and anti-seizure efficacy. The retention rate of KDT at 6 months was associated with seizure type, status epilepticus and anti-seizure efficacy. The retention rate of KDT at 12 and 24 months were both associated with anti-seizure efficacy. SIGNIFICANCE: Anti-seizure efficacy was the sole independent predictor of long-term retention. This large-scale cohort study advances the field by demonstrating the predominant role of efficacy in long-term adherence. The cohort size (N = 337), one of the largest reported, strengthens evidence that the long-term retention rate (>1 year) can be used as an important indicator to evaluate the efficacy of KDT, which is simple and reliable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.